Latest & greatest articles for opioid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on opioid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on opioid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for opioid

1. Managing Acute Pain in Patients Taking Medications for Opioid Use Disorder

Managing Acute Pain in Patients Taking Medications for Opioid Use Disorder Management Briefs eBrief-no160 -- Managing Acute Pain in Patients Taking Medications for Opioid Use Disorder Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no160 -- Managing Acute Pain in Patients Taking Medications for Opioid Use Disorder Health Services Research & Development Management eBrief (...) no. 160 » Issue 160 October 2019 The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Brief: Managing Acute Pain in Patients Taking Medications for Opioid Use Disorder Acute pain management in patients with opioid use disorder (OUD) can be challenging due to several factors including increased pain sensitivity and higher opioid tolerance. Use of medications for OUD (MOUD) including methadone, buprenorphine/naloxone, or naltrexone adds to the complexity of acute pain management

2019 Veterans Affairs - R&D

2. Barriers and Facilitators to Use of Medications for Opioid Use Disorder

Barriers and Facilitators to Use of Medications for Opioid Use Disorder Management Briefs eBrief-no159 -- Barriers and Facilitators to Use of Medications for Opioid Use Disorder Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no159 -- Barriers and Facilitators to Use of Medications for Opioid Use Disorder Health Services Research & Development Management eBrief no. 159 » Issue (...) 159 October 2019 The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder As a component of VA’s overall response to the crisis of opioid-related morbidity and mortality, VA provides treatment for those with opioid use disorder (OUD; i.e. ICD-10 opioid dependence), a diagnosis made based on symptoms (i.e., drug cravings) and behaviors (i.e., inability to cut down or control substance use despite

2019 Veterans Affairs - R&D

3. Mind-Body Therapies for Opioid-Treated Pain: A Systematic Review and Meta-analysis

Mind-Body Therapies for Opioid-Treated Pain: A Systematic Review and Meta-analysis Mind-body therapies (MBTs) are emerging as potential tools for addressing the opioid crisis. Knowing whether mind-body therapies may benefit patients treated with opioids for acute, procedural, and chronic pain conditions may be useful for prescribers, payers, policy makers, and patients.To evaluate the association of MBTs with pain and opioid dose reduction in a diverse adult population with clinical pain.For (...) this systematic review and meta-analysis, the MEDLINE, Embase, Emcare, CINAHL, PsycINFO, and Cochrane Library databases were searched for English-language randomized clinical trials and systematic reviews from date of inception to March 2018. Search logic included (pain OR analgesia OR opioids) AND mind-body therapies. The gray literature, ClinicalTrials.gov, and relevant bibliographies were also searched.Randomized clinical trials that evaluated the use of MBTs for symptom management in adults also

2019 EvidenceUpdates

4. Smaller Quantity Opioid Prescribing for Chronic Non-Cancer Pain: Clinical Effectiveness and Guidelines

Smaller Quantity Opioid Prescribing for Chronic Non-Cancer Pain: Clinical Effectiveness and Guidelines Smaller Quantity Opioid Prescribing for Chronic Non-Cancer Pain: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Smaller Quantity Opioid Prescribing for Chronic Non-Cancer Pain: Clinical Effectiveness and Guidelines Smaller Quantity Opioid Prescribing for Chronic Non-Cancer Pain: Clinical Effectiveness and Guidelines Last updated: June 28, 2019 Project Number (...) : RA1041-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of prescribing opioids in smaller quantities for patients with chronic non-cancer pain? What are the evidence-based guidelines associated with opioid prescribing for patients with chronic non-cancer pain? Key Message One non-randomized study and three evidence-based guidelines were identified regarding short-term prescribing of opioids for patient with chronic non

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines

Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Buprenorphine (...) for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Last updated: May 9, 2019 Project Number: RC1111-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of various buprenorphine or buprenorphine-naloxone formulations versus other buprenorphine formulations for the treatment of opioid use disorders during pregnancy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Smaller Quantity Opioid Prescribing for Acute Pain: Clinical Effectiveness and Guidelines

Smaller Quantity Opioid Prescribing for Acute Pain: Clinical Effectiveness and Guidelines Smaller Quantity Opioid Prescribing for Acute Pain: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Smaller Quantity Opioid Prescribing for Acute Pain: Clinical Effectiveness and Guidelines Smaller Quantity Opioid Prescribing for Acute Pain: Clinical Effectiveness and Guidelines Last updated: June 14, 2019 Project Number: RA1039-000 Product Line: Research Type: Drug Report (...) Type: Reference List Result type: Report Question What is the clinical effectiveness of prescribing opioids in smaller quantities for patients with acute pain? What are the evidence-based guidelines associated with opioid prescribing for patients with acute pain? Key Message One systematic review of guidelines, two non-randomized studies, and four evidence-based guidelines were identified regarding smaller quantity opioid prescribing for acute pain. Files Rapid Response Reference List Published

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Programs for the Treatment of Opioid Addiction in Canada

Programs for the Treatment of Opioid Addiction in Canada Programs for the Treatment of Opioid Addiction in Canada | CADTH.ca Find the information you need Programs for the Treatment of Opioid Addiction in Canada Programs for the Treatment of Opioid Addiction in Canada Last updated: September 6, 2019 Project Number: ES0335-000 Product Line: Research Type: Device Result type: Report CADTH undertook an Environmental Scan to understand the current context surrounding opioid addiction programs (...) , including both opioid agonist therapies and other non-pharmacological programming, and care setting transitions across Canada. The key objectives of this Environmental Scan were to: describe the opioid addiction treatment programs that are currently available for use in Canada and internationally identify the recommended wait times for opioid addiction treatment programs in Canada summarize the factors influencing wait times for opioid addiction treatment programs in Canada identify the patient

2019 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

8. Spread the Word: Widespread Distribution of Naloxone to Decrease Opioid-Related Deaths

Spread the Word: Widespread Distribution of Naloxone to Decrease Opioid-Related Deaths September 16, 2019 (en français) Love Tools for Practice? Want to see it in conference format? You're in luck! Visit the ACFP website for more information. Spread the Word: Widespread Distribution of Naloxone to Decrease Opioid-Related Deaths Clinical Question: Does population-based or programmatic provision of naloxone kits decrease the risk of opioid- related deaths in people who use opioids? Bottom Line (...) : Offering naloxone kits and overdose related education for people who use opioids and their community may decrease opioid related deaths by ~7 per 100,000 population over one year. Effectiveness is likely influenced by magnitude of opioid problem in a given community and other confounders (like co-ingestions, co- morbidities, type and dose of opioid used). Evidence: • Randomized controlled trial: o 1676 inmates being released from prison were randomized to kit with single dose naloxone versus

2019 Tools for Practice

9. Buprenorphine (Buvidal) - for the treatment of opioid dependence

Buprenorphine (Buvidal) - for the treatment of opioid dependence Final Appraisal Recommendation Advice No: 1119 – September 2019 Buprenorphine (Buvidal ® ) 8 mg, 16 mg, 24 mg, 32 mg, 64 mg, 96 mg and 128 mg prolonged-release solution for subcutaneous injection Submission by Camurus AB In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3977), which includes the AWMSG Secretariat Assessment Report (ASAR (...) ), the Preliminary Appraisal Recommendation (PAR) and the applicant company’s response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Buprenorphine (Buvidal ® ) is recommended as an option for use within NHS Wales for the treatment of opioid dependence within a framework of medical

2019 All Wales Medicines Strategy Group

10. Buprenorphine-Naloxone Tablet Versus Methadone for the Treatment of Patients with Opioid Use Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Buprenorphine-Naloxone Tablet Versus Methadone for the Treatment of Patients with Opioid Use Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Buprenorphine-Naloxone Tablet Versus Methadone for the Treatment of Patients with Opioid Use Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Buprenorphine-Naloxone Tablet Versus Methadone for the Treatment of Patients with Opioid Use Disorder (...) : A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Buprenorphine-Naloxone Tablet Versus Methadone for the Treatment of Patients with Opioid Use Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: July 31, 2019 Project Number: RC1150-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of buprenorphine-naloxone tablets compared with methadone

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines

Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Buprenorphine for Opioid Use Disorder: A Review of Comparative (...) Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Last updated: April 24, 2019 Project Number: RC1092-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of various buprenorphine or buprenorphine-naloxone (BUP-NAL) formulations versus other buprenorphine formulations for the treatment of opioid use disorder (OUD)? What is the clinical evidence regarding the safety of various

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Opioid Agonist Treatments for Opioid Use Disorders: A Rapid Qualitative Review

Opioid Agonist Treatments for Opioid Use Disorders: A Rapid Qualitative Review Opioid Agonist Treatments for Opioid Use Disorders: A Rapid Qualitative Review | CADTH.ca Find the information you need Opioid Agonist Treatments for Opioid Use Disorders: A Rapid Qualitative Review Opioid Agonist Treatments for Opioid Use Disorders: A Rapid Qualitative Review Last updated: April 30, 2019 Project Number: RC1100-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result (...) type: Report Question How do people with opioid use disorders, and their health care providers, understand, communicate, and make decisions related to opioid agonist treatments? How have people with opioid use disorders experienced treatment with opioid agonists? What are their perspectives on and preferences for programs that offer opioid agonist treatments? How have health care providers who care for people with opioid use disorders experienced supporting opioid agonist treatment? What

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. Evidence Brief - Barriers and Facilitators to Use of Medications for Opioid Use Disorder

Evidence Brief - Barriers and Facilitators to Use of Medications for Opioid Use Disorder 4 August 2019 Prepared for: Department of Veterans Affairs Veterans Health Administration Health Services Research & Development Service Washington, DC 20420 Prepared by: Evidence Synthesis Program (ESP) Coordinating Center Portland VA Medical Center Portland, OR Mark Helfand, MD, MPH, MS, Director Evidence Brief: Barriers and Facilitators to Use of Medication s for Opioid Use Disorder Authors: Katherine (...) report are welcome and can be sent to Nicole Floyd, Deputy Director, ESP Coordinating Center at Nicole.Floyd@va.gov. Recommended citation: Mackey K, Veazie S, Anderson J, Bourne D, and Peterson K. Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009; 2009. Posted final reports

2019 Veterans Affairs Evidence-based Synthesis Program Reports

14. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic

Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine - American Journal of Obstetrics & Gynecology Email/Username: Password: Remember me Search Terms Search within Search (...) Share this page: Access provided by Volume 221, Issue 1, Pages B5–B28 Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine The workshop was convened at the 38th Annual Pregnancy Meeting of the Society for Maternal-Fetal Medicine in Dallas, TX, January 29–February 2, 2018. x Jeffrey

2019 Society for Maternal-Fetal Medicine

15. Evidence Brief - Barriers and Facilitators to Use of Medications for Opioid Use Disorder

Evidence Brief - Barriers and Facilitators to Use of Medications for Opioid Use Disorder Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder Health Services Research & Development Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder to the ESP Report RSS feed Prepared by: Evidence (...) Synthesis Program (ESP) Coordinating Center Portland VA Health Care System Portland, OR Mark Helfand, MD, MPH, MS, Director Recommended Citation: Mackey K, Veazie S, Anderson J, Bourne D, and Peterson K. Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009; 2009. Download PDF: , Purpose

2019 Veterans Affairs Evidence-based Synthesis Program Reports

16. Evidence Brief - Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain

Evidence Brief - Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Evidence Brief: Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain Health Services Research & Development Evidence Brief: Benefits and Harms of Long-term Opioid Dose Reduction (...) or Discontinuation in Patients with Chronic Pain to the ESP Report RSS feed Prepared by: Evidence Synthesis Program (ESP) Coordinating Center Portland VA Health Care System Portland, OR Mark Helfand, MD, MPH, MS, Director Recommended Citation: Mackey K, Anderson J, Bourne D, Chen E, Peterson K. Evidence Brief: Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office

2019 Veterans Affairs Evidence-based Synthesis Program Reports

17. Evidence Brief - Managing Acute Pain in Patients with Opioid Use Disorder on Medication-assisted Treatment

Evidence Brief - Managing Acute Pain in Patients with Opioid Use Disorder on Medication-assisted Treatment Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Evidence Brief: Managing Acute Pain in Patients with Opioid Use Disorder on Medication-assisted Treatment Health Services Research & Development Evidence Brief: Managing Acute Pain in Patients with Opioid Use Disorder on Medication-assisted (...) Treatment to the ESP Report RSS feed Prepared by: Evidence Synthesis Program (ESP) Coordinating Center Portland VA Health Care System Portland, OR Mark Helfand, MD, MPH, MS, Director Recommended Citation: Veazie S, Mackey K, Bourne D, Peterson K. Evidence Brief: Managing Acute Pain in Patients with Opioid Use Disorder on Medication-Assisted Treatment. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans

2019 Veterans Affairs Evidence-based Synthesis Program Reports

18. What is the Incidence of Iatrogenic Opioid Use Disorder?

What is the Incidence of Iatrogenic Opioid Use Disorder? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca July 22 (...) , 2019 (en français) What is the Incidence of Iatrogenic Opioid Use Disorder? Clinical Question: What is the risk of developing opioid use disorder (OUD) when taking prescription opioids? Bottom Line: The incidence of OUD associated with prescribed opioids among chronic pain patients is likely ~3% (over ~2 years) but causation is uncertain. Patients with no history of substance use disorders appear to be at lower risk ( 90 days) or at higher doses (>120mg/day morphine equivalent). Evidence

2019 Tools for Practice

19. Buprenorphine (Buvidal) - Treatment of opioid dependence

Buprenorphine (Buvidal) - Treatment of opioid dependence 1 Published 12 August 2019 1 SMC2169 buprenorphine 8/16/24/32/64/96/128 mg prolonged-release solution for injection (Buvidal®) Camurus AB 5 July 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission buprenorphine (Buvidal ® (...) ) is accepted for restricted use within NHSScotland. Indication under review: Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. SMC restriction: Use in patients in whom methadone is not suitable and for whom the use of buprenorphine is considered appropriate. In a phase III study in patients with opioid dependence, subcutaneous buprenorphine was non-inferior to sublingual

2019 Scottish Medicines Consortium

20. Fentanyl (Actiq and other brands) and other opioids: risk of increased pain

Fentanyl (Actiq and other brands) and other opioids: risk of increased pain Prescrire IN ENGLISH - Spotlight ''Fentanyl (Actiq° and other brands) and other opioids: risk of increased pain'', 1 July 2019 {1} {1} {1} | | > > > Fentanyl (Actiq° and other brands) and other opioids: risk of increased pain Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Fentanyl (Actiq° and other brands) and other opioids: risk of increased pain Paradoxically, fentanyl, like other opioids, can exacerbate the pain it is intended to relieve. In 2018, the European Medicines Agency (EMA) reported 16 cases of hyperalgesia (severe pain) in patients taking transmucosal fentanyl. Hyperalgesia is a known adverse effect of opioids. The key symptom is an increase in the intensity of pain felt, an increase associated with the effects of the opioid. It is difficult to distinguish

2019 Prescrire